{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:20:04Z","timestamp":1786119604738,"version":"build-2736575974"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1097\/ico.0b013e3181d927b9","type":"journal-article","created":{"date-parts":[[2010,9,19]],"date-time":"2010-09-19T14:48:09Z","timestamp":1284907689000},"page":"1373-1379","source":"Crossref","is-referenced-by-count":22,"title":["The Effect of Subconjunctival Ranibizumab on Primary Pterygium: A Pilot Study"],"prefix":"10.1097","volume":"29","author":[{"given":"Achilleas","family":"Mandalos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Tsakpinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Karayannopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Tsinopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Karkavelas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Chalvatzis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavros","family":"Dimitrakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210204","first-page":"303","article-title":"A hypothesis on the pathogenesis of pterygia.","volume":"10","author":"Wong","year":"1978","journal-title":"Ann Ophthalmol"},{"key":"R2-6-20210204","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3109\/02713689408999878","article-title":"Immunohistochemical evidence that human pterygia originate from an invasion of vimentin-expressing altered limbal epithelial basal cells.","volume":"13","author":"Dushku","year":"1994","journal-title":"Curr Eye Res"},{"key":"R3-6-20210204","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.ophtha.2005.01.023","article-title":"Differential expression of vascular endothelial growth factor implies the limbal origin of pterygia.","volume":"112","author":"Gebhardt","year":"2005","journal-title":"Ophthalmology"},{"key":"R4-6-20210204","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/00003226-199709000-00010","article-title":"Immunolocalization of bFGF in pterygia: association with mast cells.","volume":"16","author":"Powers","year":"1997","journal-title":"Cornea"},{"key":"R5-6-20210204","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0065-1281(96)80038-9","article-title":"Immunohistochemical localization of basic fibroblast growth factor, platelet derived growth factor, transforming growth factor- and tumor necrosis factor- in the pterygia.","volume":"98","author":"Kria","year":"1996","journal-title":"Acta Histochem"},{"key":"R6-6-20210204","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/sj.eye.6702495","article-title":"Angiogenesis in pterygium: study of microvessel density, vascular endothelial growth factor, and thrombospondin-1.","volume":"21","author":"Aspiotis","year":"2007","journal-title":"Eye"},{"key":"R7-6-20210204","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1076\/ceyr.25.1.17.9959","article-title":"Angiogenesis in pterygium: Morphometric and immunohistochemical study.","volume":"25","author":"Marcovich","year":"2002","journal-title":"Curr Eye Res"},{"key":"R8-6-20210204","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00003226-200307000-00015","article-title":"Decreased pigment epithelium-derived factor and increased vascular endothelial growth factor levels in pterygia.","volume":"22","author":"Jin","year":"2003","journal-title":"Cornea"},{"key":"R9-6-20210204","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1097\/00003226-200110000-00013","article-title":"Expression of vascular endothelial growth factor and inducible nitric oxide synthase in pterygia.","volume":"20","author":"Lee","year":"2001","journal-title":"Cornea"},{"key":"R10-6-20210204","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1167\/iovs.05-1130","article-title":"UVB-mediated induction of cytokines and growth factors in pterygium epithelial cells involves cell surface receptors and intracellular signaling.","volume":"47","author":"Di Girolamo","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R11-6-20210204","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1136\/bjo.2008.145128","article-title":"Transient postoperative vascular endothelial growth factor (VEGF)-neutralisation improves graft survival in corneas with partly regressed inflammatory neovascularisation.","volume":"93","author":"Bachmann","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"R12-6-20210204","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1167\/iovs.06-0570","article-title":"Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis.","volume":"48","author":"Bock","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R13-6-20210204","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/archopht.125.6.834","article-title":"Topical bevacizumab therapy for corneal neovascularization.","volume":"125","author":"DeStafeno","year":"2007","journal-title":"Arch Ophthalmol"},{"key":"R14-6-20210204","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.ophtha.2008.02.013","article-title":"The effect of topical bevacizumab on corneal neovascularization.","volume":"115","author":"Kim","year":"2008","journal-title":"Ophthalmology"},{"key":"R15-6-20210204","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/ICO.0b013e318159019f","article-title":"Subconjunctival bevacizumab injection for corneal neovascularization.","volume":"27","author":"Bahar","year":"2008","journal-title":"Cornea"},{"key":"R16-6-20210204","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1755-3768.2008.01399.x","article-title":"Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization.","volume":"87","author":"You","year":"2009","journal-title":"Acta Ophthalmol"},{"key":"R17-6-20210204","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/ICO.0b013e31817786ad","article-title":"Subconjunctival bevacizumab for corneal neovascularization.","volume":"27","author":"Doctor","year":"2008","journal-title":"Cornea"},{"key":"R18-6-20210204","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s00417-009-1099-1","article-title":"Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization.","volume":"247","author":"Koenig","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R19-6-20210204","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1001\/archophthalmol.2009.18","article-title":"Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study.","volume":"127","author":"Dastjerdi","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"R20-6-20210204","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00417-007-0684-4","article-title":"Bevacizumab (Avastin) eye drops inhibit corneal neovascularization.","volume":"246","author":"Bock","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R21-6-20210204","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/ICO.0b013e31818d382d","article-title":"Effect of subconjunctival bevacizumab on primary pterygium.","volume":"28","author":"Teng","year":"2009","journal-title":"Cornea"},{"key":"R22-6-20210204","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00347-009-1936-y","article-title":"Antiangiogenic therapy for pterygium recurrence.","volume":"106","author":"Leippi","year":"2009","journal-title":"Ophthalmologe"},{"key":"R23-6-20210204","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/02713680701799101","article-title":"Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium.","volume":"33","author":"Bahar","year":"2008","journal-title":"Curr Eye Res"},{"key":"R25-6-20210204","first-page":"3017","article-title":"Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer.","volume":"4","author":"Giatromanolaki","year":"1998","journal-title":"Clin Cancer Res"},{"key":"R26-6-20210204","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1136\/bjo.2008.155291","article-title":"Treatment of inflamed pterygia or residual pterygial bed.","volume":"93","author":"Mansour","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"R27-6-20210204","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.mehy.2007.01.047","article-title":"Bevacizumab (Avastin) as a potential novel adjunct in the management of pterygia.","volume":"69","author":"Hosseini","year":"2007","journal-title":"Med Hypotheses"},{"key":"R28-6-20210204","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3109\/02713680903395273","article-title":"Efficacy of topical bevacizumab for inhibiting growth of impending recurrent pterygium.","volume":"35","author":"Fallah","year":"2010","journal-title":"Curr Eye Res"},{"key":"R29-6-20210204","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000252980","article-title":"Preliminary results of subconjunctival bevacizumab in primary pterygium excision.","volume":"43","author":"Razeghinejad","year":"2009","journal-title":"Ophthalmic Res"},{"key":"R30-6-20210204","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1167\/iovs.05-1071","article-title":"The role of PDGF receptor inhibitors and PI3-Kinase signaling in the pathogenesis of corneal neovascularization.","volume":"47","author":"Dell","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R31-6-20210204","doi-asserted-by":"crossref","first-page":"867","DOI":"10.2337\/diabetes.50.4.867","article-title":"Angiotensin II induces expression of the Tie2 receptor ligand, angiopoietin-2, in bovine retinal endothelial cells.","volume":"50","author":"Otani","year":"2001","journal-title":"Diabetes"}],"container-title":["Cornea"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00003226-201012000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:38:12Z","timestamp":1786041492000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00003226-201012000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/ico.0b013e3181d927b9","relation":{},"ISSN":["0277-3740"],"issn-type":[{"value":"0277-3740","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]}}}